Comparing the current results to its competitors, Phibro Animal Health reported Revenue increase in the 4 quarter 2026 by 4.4 % year on year. The revenue growth was below Phibro Animal Health's competitors' average revenue growth of 5.05 %, achieved in the same quarter.
Phibro Animal Health Corporation Net Income in the 4 quarter 2026 grew year on year by 26.05%, while most of its competitors have experienced a net loss.
Phibro Animal Health's Comment on Competition and Industry Peers
The company operates in highly competitive industries with numerous global and regional competitors, some of which possess greater financial, research and development, manufacturing, and other resources. Its competitive position depends on product registrations, customer service and support, product line breadth, product quality, manufacturing technology, facility locations, and pricing, allowing for customized solutions in animal health. Competition is present in all markets where the company operates, with many products facing alternatives or substitutes. Industry consolidation may persist.
Overall company revenue, grew less, than total company revenues, at 4.4 % and company approximately market share, declined to 2.33 %. << More on PAHC Market Share.
*Market share is calculated based on total revenue.
Publicly Traded Peers of Phibro Animal Health Corporation
Merck and Co Inc Share Performance
-3.75%
Over The Past 5 Days
Merck and Co Inc
Profile
Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.
Zoetis Inc operates as a global animal health company, offering a comprehensive range of medicines, vaccines, diagnostics, and services for both livestock and companion animals. Their business model emphasizes innovation in research and development to improve animal health, coupled with strong customer support, educational resources, and targeted solutions for veterinarians, livestock producers, and pet owners around the world.
Elanco Animal Health Incorporated Share Performance
+6.93%
This Year
Elanco Animal Health Incorporated
Profile
Elanco Animal Health Inc operates on a business model that focuses on the development, manufacturing, and marketing of veterinary products and services. They aim to provide innovative solutions for animal health and well-being, offering a range of products including medicines, vaccines, and feed additives. Elanco serves both companion animals and food-producing animals, catering to the diverse needs of veterinarians, farmers, and pet owners worldwide.
Sources:
Phibro Animal Health Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Phibro Animal Health Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
